دسترسی یکساله به بیش از ۵۰۰ ژورنال روز جهان موجود در سامانه
-
http://medilib.ir
- ﻣﺪﺕ ﺯﻣﺎﻥ : 365 ﺭﻭﺯ
قیمت : 3,800,000 تومان- قیمت ویژه : 1,900,000تومان
Creation of an Inflammatory Bowel Disease Referral Pathway for Identifying Patients Who Would Benefit From Inflammatory Bowel Disease Specialist Consultationت
Frank I Scott, MD MSCE, Orna Ehrlich, MPH, Dallas Wood, PhD, Catherine Viator, MS, Carrie Rains, MPH, Lisa DiMartino, PhD, Jill McArdle, MS, Gabrielle Adams, MD, Lara Barkoff, MD, Jennifer Caudle, DO, Jianfeng Cheng, MD, PhD, Jami Kinnucan, MD, Kimberly Persley, MD, Jennifer Sariego, RN, Samir Shah, MD, Caren Heller, MD, MBA, David T Rubin, MD
doi : 10.1093/ibd/izac216
Inflammatory Bowel Diseases, Volume 29, Issue 8, August 2023, Pages 1177Ø°1190
Recommendations regarding signs and symptoms that should prompt referral of patients with inflammatory bowel disease (IBD) to an IBD specialist for a consultation could serve to improve the quality of care for these patients. Our aim was to develop a consult care pathway consisting of clinical features related to IBD that should prompt appropriate consultation.
Ruxolitinib Alleviates Inflammation, Apoptosis, and Intestinal Barrier Leakage in Ulcerative Colitis via STAT3ت
Chunxiao Li, PhD, Yu Xu, MD, Tengjiao Gao, MD, Shunyao Zhang, MD, Zhe Lin, MD, Shaobo Gu, MD, Yi Fang, MD, Xin Yuan, MD, Siyi Yu, PhD, Qi Jiang, MD, Zhongze Lou, MD, Xiuming Zhang, MD, Jie Zhang, MD, Qiaoyan Wu, MD, Mengli Gu, PhD, Xiaoyun Ding, PhD, Jing Sun, MD, Yi Chen, MD
doi : 10.1093/ibd/izad007
Inflammatory Bowel Diseases, Volume 29, Issue 8, August 2023, Pages 1191Ø°1201
Ulcerative colitis (UC) is an idiopathic, chronic inÙƒammatory disorder of the colonic mucosa with increasing prevalence and limited management. Ruxolitinib is a new anti- JAK/STAT3 biologic agent that has shown potential in protecting against colitis.
Higher Cell-Mediated Immune Responses in Patients With Inflammatory Bowel Disease on Anti-TNF Therapy After COVID-19 Vaccination
Freddy Caldera, DO, MS, Francis A Farraye, MD, MSc, Brian M Necela, PhD, Davitte Cogen, BSc, Sumona Saha, MD, MS, Arnold Wald, MD, Nader D Daoud, MD, Kelly Chun, PhD, Ian Grimes, MD, Megan Lutz, MD, Sean R Van Helden, BS, Melanie D Swift, MD, MPH, Abinash Virk, MD, Adil E Bharucha, MBBS, MD, Tushar C Patel, MB, CHB, Gregory J Gores, MD, Saranya Chumsri, MD, Mary S Hayney, PharmD, MPH, Keith L Knutson, PhD
doi : 10.1093/ibd/izac193
Inflammatory Bowel Diseases, Volume 29, Issue 8, August 2023, Pages 1202Ø°1209
Some patients with inflammatory bowel disease (IBD) on immunosuppressive therapies may have a blunted response to certain vaccines, including the messenger RNA (mRNA) coronavirus disease 2019 (COVID-19) vaccines.
Development and Validation of a Japanese Version of the Inflammatory Bowel Disease Self-efficacy Scale and Cross-culture Study in Japan and the United Statesت
Makoto Tanaka, PhD, Aki Kawakami, PhD, Kayoko Sakagami, RN, Tomoko Terai, MLA, Jovelle Fernandez, MD, PhD, Laurie Keefer, PhD, Hiroaki Ito, MD, PhD
doi : 10.1093/ibd/izac196
Inflammatory Bowel Diseases, Volume 29, Issue 8, August 2023, Pages 1210Ø°1216
Self-efficacy is an important health outcome for patients with inflammatory bowel disease (IBD). We aimed to develop a Japanese version of the IBD-Self-Efficacy Scale (IBD-SES.J) and compare characteristics of self-efficacy of IBD patients with previously reported results from patients in the United States.
Intestinal Ultrasound to Assess Ulcerative Colitis Disease Activity in Children: External Validation and Comparison of 2 Intestinal Ultrasound Activity Indicesت
Elsa A van Wassenaer, MD, PhD, Rick R van Rijn, MD, PhD, Sabrina L M Zwetsloot, Floris A E de Voogd, MD, PhD, Joost van Schuppen, MD, PhD, Angelika Kindermann, MD, PhD, Tim G J de Meij, MD, PhD, Johan E van Limbergen, MD, PhD, K B Gecse, Geert R DصHaens, MD, PhD, Marc A Benninga, MD, PhD, Bart G P Koot, MD, PhD on behalf of the RAINBOW group
doi : 10.1093/ibd/izac197
Inflammatory Bowel Diseases, Volume 29, Issue 8, August 2023, Pages 1217Ø°1222
There is currently no consensus on the definition of an abnormal intestinal ultrasound (IUS) for children with ulcerative colitis (UC). This cross-sectional study aimed to externally validate and compare 2 existing IUS indices in children with UC.
Osteonecrosis in Inflammatory Bowel Disease: Clinical Features, Risk Factor Analysis, and Outcomesت
Zeinab Bakhshi, MD, Siddhant Yadav, MD, W Scott Harmsen, MS, Jithinraj Edakkanambeth Varayil, MD, Kevin A Karls, MD, William J Tremaine, MD, Edward V Loftus, Jr, MD
doi : 10.1093/ibd/izac198
Inflammatory Bowel Diseases, Volume 29, Issue 8, August 2023, Pages 1223Ø°1230
Avascular necrosis (AVN) is a known adverse event associated with corticosteroid (CS) usage. Inflammatory bowel disease (IBD) is often treated with a CS for induction of remission. We sought to describe clinical features and outcomes of IBD patients with AVN.
Impact of Crohnصs Disease Therapies on Histology in Randomized Controlled Trials: Systematic Review With Meta-analysisت
Joana Roseira, MD, Mafalda Santiago, PhD, Maria Manuela Estevinho, MD, Paula Moreira, Catarina Alves, Silvio Danese, PhD, Laurent Peyrin-Biroulet, PhD, Axel Dignass, PhD, Roger Feakins, PhD, Fernando Magro, PhD
doi : 10.1093/ibd/izac203
Inflammatory Bowel Diseases, Volume 29, Issue 8, August 2023, Pages 1231Ø°1243
The effectiveness of Crohnصs disease treatments for inducing histological outcomes has not been addressed systematically. We performed a systematic review and meta-analysis of randomized controlled trials in Crohnصs disease to assess the impact of therapies on mucosal histopathology.
The Impact of Disease Activity on Sexual and Erectile Dysfunction in Patients With Inflammatory Bowel Diseaseت
Thomas C Mules, MBChB, Akhilesh Swaminathan, MBChB, Esther Hirschfeld, MBBS, Grace M Borichevsky, MSc, Chris M Frampton, PhD, Andrew S Day, MD, Richard B Gearry, PhD
doi : 10.1093/ibd/izac204
Inflammatory Bowel Diseases, Volume 29, Issue 8, August 2023, Pages 1244Ø°1254,
Increased disease activity may be a risk factor for sexual dysfunction (SD) in patients with inflammatory bowel disease (IBD). This study investigated associations between objective measures of disease activity and sexual function.
Concordance and Discordance Between Patient-reported Remission, Patient-reported Outcomes, and Physician Global Assessmentت
Kendra J Kamp, PhD, Stephen E Hawes, PhD, Chung Sang Tse, MD, Siddharth Singh, MD, Nhu Dang, BA, Ridhima Oberai, BS, S Alandra Weaver, MPH, Gil Y Melmed, MD, MS, Corey A Siegel, MD, MS, Welmoed K van Deen, PhD, MD, IBD Qorus
doi : 10.1093/ibd/izac206
Inflammatory Bowel Diseases, Volume 29, Issue 8, August 2023, Pages 1255Ø°1262
Although validated patient-reported outcome (PRO) measurements can categorize patients with inflammatory bowel disease (IBD) into clinical remission or active disease, patients may have different definitions of remission.ت
Ulcer Size After Induction Therapy Performs Better Than Symptom Assessment for Prediction of One Year Endoscopic Remission in Crohnصs Disease: A Post Hoc Analysisت
Cara Pray, MD,تEmily C L Wong, BHSc,تAchuthan Aruljothy, MDCM,تParambir S Dulai, MD,تJohn K Marshall, MD, MSc,تWalter Reinisch, MD, PhD,تNeeraj Narula, MD, MPH
doi : 10.1093/ibd/izac210
Inflammatory Bowel Diseases, Volume 29, Issue 8, August 2023, Pages 1263Ø°1271
We evaluated whether postinduction ulcer size and patient-reported outcome (PRO) severity are associated with the achievement of 1-year endoscopic remission (ER) in patients with Crohnصs disease (CD).
Hepcidin and Iron Status in Patients With Inflammatory Bowel Disease Undergoing Induction Therapy With Vedolizumab or Infliximabت
Roberta Loveikyte, MD, Arno R Bourgonje, MD, PhD, Johannes J van der Reijden, MSc, Marian L C Bulthuis, MSc, Lukas J A C Hawinkels, PhD, Marijn C Visschedijk, MD, PhD, Eleonora A M Festen, MD, PhD, Hendrik M van Dullemen, MD, PhD, Rinse K Weersma, MD, PhD, Harry van Goor, PhD, Andrea E van der Meulen-de Jong, MD, PhD, Gerard Dijkstra, MD, PhD
doi : 10.1093/ibd/izad010
Inflammatory Bowel Diseases, Volume 29, Issue 8, August 2023, Pages 1272Ø°1284
Hepcidin, the systemic iron regulator, could be critical in differentiating iron deficiency (ID) from functional iron restriction in inflammatory bowel disease (IBD). We assessed hepcidin as a diagnostic ID marker and explored the relationship between hepcidin and its regulators in patients with IBD undergoing induction therapy with infliximab (IFX) or vedolizumab (VEDO).
Myeloid FTH1 Deficiency Protects Mice From Colitis and Colitis-associated Colorectal Cancer via Reducing DMT1-Imported Iron and STAT3 Activation
Zhaoli Liu, PhD, Mariella Arcos, MS, David R Martin, MD, Xiang Xue, PhD
doi : 10.1093/ibd/izad009
Inflammatory Bowel Diseases, Volume 29, Issue 8, August 2023, Pages 1285Ø°1296
Myeloid cells are critical for iron and immune homeostasis. Ferritin heavy chain (FTH1) is essential for intracellular iron storage. Myeloid FTH1 is important in the pathogenesis of many inflammatory diseases. However, the role of myeloid FTH1 in colitis and colitis-associated cancer has not been determined.
Differential Brain Structural and Functional Patterns in Crohnصs Disease Patients are Associated with Different Disease Stages
Alessandro Agostini, PhD, Francesca Benuzzi, PhD, Daniela Ballotta, PhD, Fernando Rizzello, PhD, Paolo Gionchetti, PhD, Nicola Filippini, PhD
doi : 10.1093/ibd/izad029
Inflammatory Bowel Diseases, Volume 29, Issue 8, August 2023, Pages 1297Ø°1305
Crohnصs disease (CD) is an inflammatory, chronic disorder that alternates between a quiescent phase and inflammatory flare-ups. Research has begun to elucidate the impact of CD in modulating brain structure and function. The previous neuroimaging studies mainly involved CD patients in remission (CD-R); therefore, little is known about how inflammation influences brain-related features in different stages of the disease. We carried out a magnetic resonance imaging (MRI) study to explore whether the different levels of disease activity may differentially affect brain structure and function.
Renal and Urological Disorders Associated With Inflammatory Bowel Diseaseت
Shankar Kumar, MBBS, MSc, Richard Pollok, PhD, David Goldsmith, MA, MB Chir
doi : 10.1093/ibd/izac140
Inflammatory Bowel Diseases, Volume 29, Issue 8, August 2023, Pages 1306Ø°1316
Renal and urinary tract complications related to inflammatory bowel disease (IBD) have been relatively understudied in the literature compared with other extraintestinal manifestations. Presentation of these renal manifestations can be subtle, and their detection is complicated by a lack of clarity regarding the optimal screening and routine monitoring of renal function in IBD patients.
(Re)Appraising Remission in Ulcerative Colitis
Ajit Sood, DM, Arshdeep Singh, DM, Ramit Mahajan, DM, Vandana Midha, MD, Charles N Bernstein, MD, David T Rubin, MD
doi : 10.1093/ibd/izac170
Inflammatory Bowel Diseases, Volume 29, Issue 8, August 2023, Pages 1317Ø°1326
As the therapeutic targets in ulcerative colitis (UC) shift from control of symptoms to mucosal healing and prevention of disease complications like disability, colectomy, and cancer, the definition of remission has evolved.
The Underappreciated Role of Secretory IgA in IBDت
Giorgos Bamias, MD, PhD,تKonstantina Kitsou, MD,تJesœs Rivera-Nieves, MD
doi : 10.1093/ibd/izad024
Inflammatory Bowel Diseases, Volume 29, Issue 8, August 2023, Pages 1327Ø°1341
Eighty percent of antibody secreting cells (ASCs) are found in the intestine, where they produce grams of immunoglobulin (Ig) A daily.ت
Model-informed Precision Dosing for Biologics Is Now Available at the Bedside for Patients With Inflammatory Bowel Disease
Ruben J Colman, MD,تAbigail Samuels, MD,تTomoyuki Mizuno, PhD,تNieko Punt, MSc,تAlexander A Vinks, PhD, PharmD,تPhillip Minar, MD, MS
doi : 10.1093/ibd/izac237
Inflammatory Bowel Diseases, Volume 29, Issue 8, August 2023, Pages 1342Ø°1346
Clonal Patterns Between Pouch Neoplasia and Prior Colorectal Neoplasia in Inflammatory Bowel Disease Patients: An Exploratory Cohort Studyت
Maarten te Groen, MD, PhD,تLauranne A A P Derikx, MD, PhD,تLisa van Lierop, MD,تBauke Ylstra, MD, PhD,تFrank Hoentjen, MD, PhD,تIris D Nagtegaal, MD, PhD,تFemke Simmer, MSc, PhDت
doi : 10.1093/ibd/izad112
Inflammatory Bowel Diseases, Volume 29, Issue 8, August 2023, Pages 1347Ø°1351,
Upadacitinib as a Novel Treatment in Therapy Refractory Collagenous Colitis
Leo Boneschansker, MD, PhD,تKristin E Burke, MD, MPH
doi : 10.1093/ibd/izad085
Inflammatory Bowel Diseases, Volume 29, Issue 8, August 2023, Pages 1352Ø°1353
Low-density Granulocytes as a Novel Biomarkers of Disease Activity in IBD
Nannan Zhu, MS,تJiejie Zhu, PhD,تQiao Mei, PhD
doi : 10.1093/ibd/izad136
Inflammatory Bowel Diseases, Volume 29, Issue 8, August 2023, Page e31
Response to Low-density Granulocytes as Novel Biomarkers of Disease Activity in IBDت
Kangzhe Xie, BSc Adv. Hons,تTamara Ortiz Cerda, PhD,تAngie Schroder, BMedSci. Hons,تNicolette Shiung, BMedSci. Hons,تBruno Lemos Wimmer, B Life Sci,تBelal Chami, PhD,تPaul K Witting, PhD
doi : 10.1093/ibd/izad133
Inflammatory Bowel Diseases, Volume 29, Issue 8, August 2023, Page e32
How to Choose a Treatment for Immune Checkpoint Inhibitor-associated Colitis: Biologics, or Fecal Microbial Transplantation
He-ran Wang, MB,تMeng-yao Wang, MB,تLi-xuan Sang, MD, PhD
doi : 10.1093/ibd/izad071
Inflammatory Bowel Diseases, Volume 29, Issue 8, August 2023, Pages e33Ø°e34
